SABCS 2015: Good News for Patients With HER2-positive Breast Cancer
T-DM1, a HER2-targeted antibody-drug conjugate, improved outcomes for patients with HER2-positive, metastatic breast cancer that had progressed despite prior...
Category: Meetings
T-DM1, a HER2-targeted antibody-drug conjugate, improved outcomes for patients with HER2-positive, metastatic breast cancer that had progressed despite prior...
Breast-conserving surgery may be a better option than mastectomy for patients with early-stage breast cancer.
Adding denosumab (Xgeva) to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal women with early-stage hormone receptor-positive breast...
Studies presented at this year’s San Antonio Breast Cancer Symposium shed light on new investigational therapies for patients with...
The AACR’s disparities conference covered a wide array of issues this year, from the biological factors that make some...
Kimberly Stegmaier, MD, co-director of the pediatric hematologic malignancy program and associate professor of pediatrics at Dana-Farber Cancer Institute...
Levi Garraway, MD, PhD, co-chair of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston Nov....
Later today, more than 200 scientists working diligently to advance the field of epigenetics research will convene in Atlanta...
The inaugural International Cancer Immunotherapy Conference, hosted jointly by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy...
China, a nation of 1.3 billion people, is facing an ongoing cancer epidemic, with more than 3 million people...